New scan agent aims to light up hard-to-find cancers
NCT ID NCT07052760
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 34 times
Summary
This study was designed to see if a new radioactive imaging agent (111In-ABD147) can help detect metastatic solid tumors, including prostate cancer and neuroendocrine tumors. The agent targets a protein called DLL3 found on many cancer cells. The trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION RESISTANT PROSTATE CANCER (CRPC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.